Cisplatin resistance in head and neck squamous cell carcinoma is linked to DNA damage response and cell cycle arrest transcriptomics rather than poor drug uptake

Abstract

Aim: Cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) is thought to involve both reduced drug uptake and altered molecular responses. However, the relative contribution of these mechanisms remains unclear.

Methods: Two HNSCC cell lines with differing sensitivity (HNO97 and HNO41) were analyzed using cytotoxicity assays, atomic absorption spectroscopy-based quantification of intracellular cisplatin, caspase 3/7 assays, Western blotting, polymerase chain reaction (PCR)-based transcriptomic analysis of DNA damage response and cell cycle arrest pathways, and RNA-seq data from The Cancer Genome Atlas (TCGA) to characterize the resistance phenotype.

Results: HNO97 (IC₅₀ = 440 µM) was 7.6-fold more resistant to cisplatin than HNO41 (IC₅₀ = 57.8 µM; P = 0.0286). After quantifying intracellular uptake (pg Pt/µg protein) and normalizing cytotoxicity to intracellular drug levels, HNO97 (IC₅₀ = 778.9 pg Pt/µg protein) remained 5-fold more resistant than HNO41 (IC₅₀ = 153.5 pg Pt/µg protein), indicating only a partial reduction in resistance (33% decrease, from 7.6-fold to 5-fold; P = 0.0286). At cisplatin concentrations yielding comparable intracellular exposure (HNO97: 440 µM; HNO41: 196 µM; both ≈ 725 pg Pt/µg protein), caspase 3/7 activation and induction of CDKN1A, GADD45A, GADD45G, and PPP1R15A were weaker in HNO97 than in HNO41. Notably, baseline expression of these genes was significantly higher in HNO97. In the TCGA cohort, multivariate analysis showed that high FANCD2 expression was associated with unfavorable recurrence-free survival in platinum-treated patients (hazard ratio = 4.0; P = 0.011), but not in those who did not receive platinum chemotherapy.

Conclusion: Cisplatin resistance in HNSCC appears to be driven primarily by molecular mechanisms involving DNA damage response and cell cycle arrest pathways, rather than poor drug uptake.

Keywords

Cisplatin resistance / head and neck squamous cell carcinoma / drug uptake / DNA damage / recurrence-free survival

References

[1] Shetty AV.Systemic treatment for squamous cell carcinoma of the head and neck.Otolaryngol Clin North Am2017;50:775-82

[2] Goel B,Pandey RK.Therapeutic approaches for the treatment of head and neck squamous cell carcinoma - an update on clinical trials.Transl Oncol2022;21:101426 PMCID:PMC9046875

[3] Li Y,Gan Y,Qin Y.Radiotherapy plus cetuximab or cisplatin in head and neck squamous cell carcinoma: an updated systematic review and meta-analysis of randomized controlled trials.Eur Arch Otorhinolaryngol2023;280:11-22

[4] Griso AB,Castelo B,Sastre-Perona A.Mechanisms of cisplatin resistance in HPV negative head and neck squamous cell carcinomas.Cells2022;11:561 PMCID:PMC8834318

[5] Stewart DJ.Mechanisms of resistance to cisplatin and carboplatin.Crit Rev Oncol Hematol2007;63:12-31

[6] Amable L.Cisplatin resistance and opportunities for precision medicine.Pharmacol Res2016;106:27-36

[7] Burger H,Eechoute K,Mathijssen RH.Drug transporters of platinum-based anticancer agents and their clinical significance.Drug Resist Updat2011;14:22-34

[8] D’Andrea AD.The Fanconi anaemia/BRCA pathway.Nat Rev Cancer2003;3:23-34

[9] Ma X,Du W.ERCC1 plays an important role in predicting survival outcomes and treatment response for patients with HNSCC: a meta-analysis.Oral Oncol2015;51:483-92

[10] Ciaparrone M,Bicciolo G.Predictive role of ERCC1 expression in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation.Oncology2015;89:227-34

[11] Köberle B,Kausch I,Ferris RL.Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo.Int J Oncol2010;36:1277-84

[12] Vaezi A,Buch S.XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.Clin Cancer Res2011;17:5513-22 PMCID:PMC3156890

[13] Burkitt K.Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines.Cancer Lett2007;253:131-7

[14] Su WP,Wu CK.Chronic treatment with cisplatin induces chemoresistance through the TIP60-mediated Fanconi anemia and homologous recombination repair pathways.Sci Rep2017;7:3879 PMCID:PMC5478611

[15] Gadhikar MA,Alves MV.Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.Mol Cancer Ther2013;12:1860-73 PMCID:PMC3955083

[16] Robinson AM,Redlich NJ.Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma.Cell Death Dis2019;10:867 PMCID:PMC6856201

[17] Chaudhary RK,Mateti UV,Shetty J.Identification of hub genes involved in cisplatin resistance in head and neck cancer.J Genet Eng Biotechnol2023;21:9 PMCID:PMC9886788

[18] Theile D,Herold-Mende C.Evaluation of drug transporters’ significance for multidrug resistance in head and neck squamous cell carcinoma.Head Neck2011;33:959-68

[19] Peters T,Haefeli WE.Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.Naunyn Schmiedebergs Arch Pharmacol2006;372:291-9

[20] U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Bioanalytical method validation: guidance for industry. 2018. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf. [Last accessed on 4 Sep 2025]

[21] Livak KJ.Analysis of relative gene expression data using real-time quantitative PCR and the 2^-ΔΔCT method.Methods2001;25:402-8

[22] Sikder RK,Uzzo RN.Differential effects of clinically relevant N- versus C-terminal truncating CDKN1A mutations on cisplatin sensitivity in bladder cancer.Mol Cancer Res2021;19:403-13 PMCID:PMC7925368

[23] Koster R,Timmer-Bosscha H.Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer.J Clin Invest2010;120:3594-605 PMCID:PMC2947220

[24] Zhan Z,Shi J,Ye M.Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors and potential therapeutic agents (Review).Exp Ther Med2025;29:82 PMCID:PMC11904865

[25] Zamagni A,Pirini F.CDKN1A upregulation and cisplatin-pemetrexed resistance in non-small cell lung cancer cells.Int J Oncol2020;56:1574-84 PMCID:PMC7170038

[26] Chaisaingmongkol J,Warta R.Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma.Oncogene2012;31:5108-16

[27] Zhang L,Wu X.Expression analysis of FANCD2 in endometrial carcinoma.Cancer Manag Res2024;16:1715-25 PMCID:PMC11626963

[28] Wu CK,Wu CL.APLF facilitates interstrand DNA crosslink repair and replication fork protection to confer cisplatin resistance.Nucleic Acids Res2024;52:5676-97 PMCID:PMC11162786

[29] Xie X,Du F.Pan-cancer analysis of the tumorigenic role of Fanconi anemia complementation group D2 (FANCD2) in human tumors.Genomics2024;116:110762

[30] Chen YF,Wang HC.Identification of arnicolide C as a novel chemosensitizer to suppress mTOR/E2F1/FANCD2 axis in non-small cell lung cancer.Br J Pharmacol2024;181:1221-37

[31] Dai CH,Chen P,Wu M.RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.J Biomed Sci2015;22:77 PMCID:PMC4575453

[32] Chirnomas D,de la Vega M.Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway.Mol Cancer Ther2006;5:952-61

[33] Andersson A,Lewensohn R.Pharmacokinetics of cisplatin and its monohydrated complex in humans.J Pharm Sci1996;85:824-7

[34] Martens-de Kemp SR,Wijnolts FM.DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells.PLoS One2013;8:e61555 PMCID:PMC3629194

[35] Mezencev R.Interactions of cisplatin with non-DNA targets and their influence on anticancer activity and drug toxicity: the complex world of the platinum complex.Curr Cancer Drug Targets2015;14:794-816

[36] Mondal P.Emerging role of non-coding RNAs in resistance to platinum-based anti-cancer agents in lung cancer.Front Pharmacol2023;14:1105484 PMCID:PMC9909610

[37] Deng Z,Liu G.Unlocking the potential of platinum drugs: organelle-targeted small-molecule platinum complexes for improved anticancer performance.RSC Chem Biol2023;4:1003-13 PMCID:PMC10685827

[38] Ferraro G,Chiaverini L.Cisplatin binding to angiogenin protein: new molecular pathways and targets for the drug’s anticancer activity.Dalton Trans2023;52:9058-67

[39] Stornetta A,Cimino GD,Sturla SJ.DNA adducts from anticancer drugs as candidate predictive markers for precision medicine.Chem Res Toxicol2017;30:388-409 PMCID:PMC5379252

[40] Parker RJ,Bostick-Bruton F.Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.J Clin Invest1991;87:772-7 PMCID:PMC329864

[41] Loh SY,Kelland LR,Harrap KR.Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.Br J Cancer1992;66:1109-15 PMCID:PMC1978040